News & Events – Page 7 – Sumitovant

Select Company

August 27, 2019Myovant Sciences to Participate in Upcoming September Investor Conferences
August 27, 2019CORRECTION: Myovant Sciences to Participate in Upcoming September Investor Conferences
August 20, 2019Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 2 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
August 06, 2019Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for First Fiscal Quarter Ended June 30, 2019
July 23, 2019Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and Positive Results from Bioequivalence Study
July 22, 2019Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, July 23rd to Discuss Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and from Bioequivalence Study
July 10, 2019Myovant Sciences and Evidation Health Announce Partnership and Launch Digital Insights Study on Menstruation
June 04, 2019Myovant Sciences to Present at Upcoming June Investor Conferences
May 30, 2019Myovant Sciences Announces Pricing of $125 Million Public Offering of Common Shares
May 29, 2019Myovant Sciences Announces $100 Million Public Offering of Common Shares
« Previous 1 … 5 6 7 8 Next »